UNASSIGNED: CTCs were isolated from the peripheral blood samples of 68 glioma patients and analyzed using DNA-seq and immunofluorescence staining. Subsequently, the clinical information of both glioma patients and matched individuals was collected for analyses. ROC curve was performed to evaluate the efficiency of the KR-based identification method. Finally, CTC images were captured and used for developing a CTC recognition algorithm.
UNASSIGNED: KR was a better parameter than cell size for identifying glioma CTCs. We demonstrated that low CTC counts were independently associated with isocitrate dehydrogenase (IDH) mutations (p = 0.024) and 1p19q co-deletion status (p = 0.05), highlighting its utility in predicting oligodendroglioma (area under the curve = 0.770). The accuracy, sensitivity, and specificity of our algorithm were 93.4%, 81.0%, and 97.4%, respectively, whereas the precision and F1 score were 90.9% and 85.7%, respectively.
UNASSIGNED: Our findings remarkably increased the efficiency of detecting glioma CTCs and revealed a correlation between CTC counts and patients\' clinical characteristics. This will allow researchers to further investigate the clinical utility of CTCs. Moreover, our automatic recognition algorithm can maintain high precision in the CTC identification process, shorten the time and cost, and significantly reduce the burden on clinicians.
■从68例神经胶质瘤患者的外周血样本中分离CTC,并使用DNA-seq和免疫荧光染色进行分析。随后,我们收集神经胶质瘤患者和配对个体的临床信息进行分析.进行ROC曲线以评估基于KR的鉴定方法的效率。最后,捕获CTC图像并将其用于开发CTC识别算法。
■KR是识别神经胶质瘤CTC比细胞大小更好的参数。我们证明,低CTC计数与异柠檬酸脱氢酶(IDH)突变(p=0.024)和1p19q共缺失状态(p=0.05)独立相关,强调其在预测少突胶质细胞瘤中的效用(曲线下面积=0.770)。准确性,灵敏度,我们的算法的特异性为93.4%,81.0%,和97.4%,分别,而精密度和F1评分分别为90.9%和85.7%,分别。
■我们的发现显着提高了检测神经胶质瘤CTC的效率,并揭示了CTC计数与患者临床特征之间的相关性。这将允许研究人员进一步研究CTC的临床效用。此外,我们的自动识别算法可以在CTC识别过程中保持较高的精度,缩短时间和成本,并显著减轻临床医生的负担。